| P2093 | author name string | John P Sabo | |
| | Mabrouk Elgadi | |
| | Fenglei Huang | |
| | Benjamin Lang | |
| P2860 | cites work | Chronic hepatitis C: future treatment | Q26824075 |
| | HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality | Q27488220 |
| | Evolving epidemiology of hepatitis C virus | Q29619973 |
| | The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 |
| | The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity | Q35804348 |
| | Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation | Q36055339 |
| | Drug interactions between antiretrovirals and hormonal contraceptives. | Q38083080 |
| | Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease | Q39658512 |
| | P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro | Q40529116 |
| | Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients. | Q42190800 |
| | Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone | Q42208297 |
| | Hepatitis C infection and presence of advanced fibrosis: wait or treat? Why wait? There is no time to lose, is there? | Q42987355 |
| | Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. | Q42988738 |
| | Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. | Q42990229 |
| | Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection | Q43031852 |
| | The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir | Q43041878 |
| | Race but not age affects erythromycin breath test results in older hypertensive men. | Q43554159 |
| | The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol | Q45013763 |
| | Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail | Q46807641 |
| | EASL Clinical Practice Guidelines: management of hepatitis C virus infection | Q86939378 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| | levonorgestrel | Q416950 |
| | Hepatitis C virus | Q708693 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 514-519 | |
| P577 | publication date | 2014-11-10 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers | |
| P478 | volume | 59 | |